The Trump administration released two rules to lower prescription drug prices and PhRMA has filed an official complaint regarding the previous importation rule.

Maryland Federal District Court ruled on the Medicaid Drug Rebate Program and the Supreme Court heard arguments to overturn the Affordable Care Act.

Just days after Vice President Biden won the presidential election, a COVID-19 vaccine was announced and the Supreme Court plans to hear arguments on the ACA.

The final rule on price transparency was released and a drug price watchdog reported that generic drug prices are beginning to rise.

The first FDA approved COVID-19 treatment may not be as effective as the high price tag makes it out to be and COVID-19 vaccines are expected to be free for everyone once approved.

The Government Accountability Office (GAO) confirmed they will review the legality of Trump's drug discount cards and Biden announced a drug pricing plan similar to Germany's model.

The Supreme Court heard arguments to allow states to regulate PBMs and the RAND corporation compared insulin prices in the US to 32 other OECD countries.

Drug company CEOs met with House Oversight and Reform Committee to discuss high drug prices; House democrats argued that Trump's $200 drug discount cards are election bribes; and President Trump tested positive for COVID-19.

Most of President Trump's plans to lower drug prices will not take effect until after the election and recent studies show they will do little to actually lower costs.

Congress urged HHS to protect the 340B program while President Trump announced he will lower drug prices with discount cards for seniors.

President Trump released his most favored nation executive order and 340B Health threatened legal action against the drug manufacturers that have limited their 340B discounts.

President Trump plans to meet with pharmaceutical executives to discuss his upcoming executive order, meanwhile drug manufacturers are using his July drug pricing executive orders to defend their withdrawal from the 340B program.

Pharmaceutical executives suggested biased alternatives to President Trump's upcoming most favored nation executive order and a recent AHIP survey found that while individuals support Trump's intention to lower drug prices, they do not support his rebate rule.